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Ischemia reperfusion injury
provokes adverse left ventricular
remodeling in dysferlin‑deficient
hearts through a pathway
that involves TIRAP dependent
signaling
Sarah Evans1, Carla J. Weinheimer1, Attila Kovacs1, Jesse W. Williams2,
Gwendalyn J. Randolph2, Wenlong Jiang1, Philip M. Barger1 & Douglas L. Mann1*
Cardiac myocytes have multiple cell autonomous mechanisms that facilitate stabilization and repair
of damaged sarcolemmal membranes following myocardial injury. Dysferlin is a protein which
facilitates membrane repair by promoting membrane resealing. Although prior studies have shown
that dysferlin-deficient (Dysf−/−) mouse hearts have an impaired recovery from acute ischemia/
reperfusion (I/R) injury ex vivo, the role of dysferlin in mediating the recovery from myocardial injury
in vivo is unknown. Here we show that Dysf−/− mice develop adverse LV remodeling following I/R injury
secondary to the collateral damage from sustained myocardial inflammation within the infarct zone.
Backcrossing Dysf−/− mice with mice lacking signaling through the Toll-Interleukin 1 Receptor DomainContaining Adaptor Protein (Tirap−/−), attenuated inflammation and abrogated adverse LV remodeling
following I/R injury. Subsequent studies using Poloxamer 188 (P188), a membrane resealing reagent,
demonstrated that P188 did not attenuate inflammation nor prevent adverse LV remodeling in Dysf−/−
mice following I/R injury. Viewed together these studies reveal a previously unappreciated role for the
importance of membrane sealing and the resolution of inflammation following myocardial injury.
The sarcolemmal phospholipid bilayer membrane that envelopes cardiac myocytes is essential for cell viability by
providing a structural barrier function that separates the cytosolic components of the cell from the extracellular
environment, as well as a crucial functional role by integrating important cellular functions, such as excitation
contraction coupling. Given the importance of the sarcolemma to cell viability, it is not surprising that cardiac
myocytes have multiple cell autonomous mechanisms that facilitate stabilization and repair of damaged sarcolemmal membranes. These include sarcolemma phospholipid rearrangements at the site of very small disruptions/
injury in order to promote membrane resealing, as well as several endogenous mechanisms that are activated in
order to repair damage to preserve muscle cell integrity and viability (reviewed in1,2).
In myocardial ischemia–reperfusion (I/R) injury the integrity of the cardiac sarcolemma is severely stressed
during ischemia and reperfusion, which leads to membrane tears, blebbing and rupture, and directly contributes
to cardiac myocyte dysfunction and cardiac myocyte cell d
 eath3. The loss of sarcolemmal barrier function can
also lead to additional myocardial damage days to weeks following reperfusion secondary to the brisk inflammatory response that ensues following the release of damage associated molecular patterns [DAMPs] by dying
cells. DAMPs released by necrotic cardiac myocytes are sufficient to provoke a brisk inflammatory response in
the heart that requires intact signaling through Toll-like receptors (TLR4) that are present on the cell surface of
cardiac myocytes and cardiac resident immune c ells4,5.
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Figure 1.  Effect of ischemia reperfusion (I/R) injury in WT, Dysf−/−, Tirap−/− and Dysf−/−/Tirap−/− mouse hearts.
WT (n = 11), Dysf−/− (n = 17), Tirap−/− (n = 9), Dysf−/−/Tirap−/− (n = 8) mice underwent closed chest ischemia
(60 min) followed by 2 to 4 weeks of reperfusion. Mice were imaged by 2-D echocardiography at baseline (preischemia), during the imposition of ischemia, and at 2 and 4 weeks. (A) Area-at-risk (AAR(SWMSI)), (B) Left
ventricular end-diastolic volume (EDV), (C) Left ventricular end systolic volume (ESV) (*p < 0.05 compared
to WT), (D) Representative images of trichrome staining of histological myocardial sections. 2 weeks after
reperfusion, (E) Group data for trichrome staining (expressed as a % of the LV myocardium) 2 weeks after
reperfusion (n = 6–12 per group), (F) Representative images and group data for Evans Blue dye (EBD) uptake
(expressed as a % of the LV myocardium) 2 weeks after reperfusion (n = 9–12 images/group). Scale bar = 100 µm.
Data are presented as mean ± SEM (*p < 0.05).
We have shown previously that tumor necrosis factor (TNF), a pro-inflammatory cytokine released by cardiac
myocytes and immune cells in response to ischemic tissue injury, confers cytoprotective responses in the heart
that are mediated, at least in part, through the upregulation of an emergency response gene termed d
 ysferlin6–8,
that has been implicated in mediating rapid membrane repair through its ability to direct intracellular vesicles
to sites of membrane i njury9. Prior studies from this and other laboratories have shown that hearts from dysferlin-deficient mice have an impaired ability to recover from acute ischemia/reperfusion (I/R) injury ex vivo8,10.
However, the role of dysferlin in chronic models of myocardial injury, wherein the heart is exposed to the dual
mechanical stresses imposed by left ventricular (LV) remodeling and activation of the sympathetic nervous system, as well as the stress imposed by activation of the innate immune response, is not known. Here we show that
mice lacking dysferlin (Dysf−/− mice) undergo adverse LV cardiac remodeling following I/R injury secondary to
increased myocardial inflammation that is mediated by Toll-Interleukin 1 Receptor (TIR) Domain-Containing
Adaptor Protein (TIRAP) signaling in the heart.

Results

Ischemia–reperfusion injury provokes adverse LV remodeling in dysferlin deficient mice
through a TIRAP dependent pathway. We previously identified dysferlin as a cytoprotective protein

that mediates the beneficial effects of TNF/TRAF2 signaling in Langendorff buffer perfused hearts subjected to
no-flow ischemia reperfusion injury8. To extend these studies in vivo, wherein the extent of tissue injury can be
modulated by the autonomic nervous system and the immune system, we performed closed-chest ischemia reperfusion studies in wild-type (WT) and Dysf−/− mice. Figure 1 shows that LV remodeling was significantly greater
in the Dysf−/− hearts when compared to WT mouse hearts. LV end-diastolic volume (EDV) (Fig. 1B) (p < 0.001 at
2 and 4 weeks of reperfusion), end-systolic volume (ESV) (Fig. 1C) (p = 0.003 at 2 weeks and p = 0.004 at 4 weeks
of reperfusion), and LV mass (LVM) (p = 0.008 at 2 weeks, p < 0.001 at 4 weeks) were significantly increased in
Dysf−/− hearts compared to WT (Supplemental Figure S1), whereas the LV ejection fraction (LVEF) was significantly decreased (p < 0.001 at both 2 and 4 weeks) in the Dysf−/− hearts. Although the area-at-risk (AAR) was
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not significantly different (p > 0.999) in WT and Dysf−/− mice, the infarct size by Masson’s trichrome staining
was significantly greater (p = 0.003) in Dysf−/− hearts when compared to WT at 2 weeks (Fig. 1D,E). Consistent
with our prior studies ex vivo8, the uptake of Evans Blue dye (EBD) was significantly increased (p = 0.02) in the
hearts of Dysf−/− mice when compared to WT hearts (Fig. 1F), suggesting that there was increased cell necrosis.
In order to determine the mechanism(s) for the adverse LV remodeling in the Dysf−/− mouse hearts, we
backcrossed Dysf−/− mice with mice lacking the Toll-Interleukin 1 Receptor (TIR) Domain-Containing Adaptor
Protein (TIRAP), which is involved in bridging the myeloid differentiation primary response gene 88 (MyD88) to
the receptor complex for TLR2 and TLR4 signaling in response to bacterial infection or tissue injury, in order to
generate Dysf−/−/Tirap−/− double knock out mice. The rationale for these studies was two-fold: first, we and others
have shown the release of damage associated molecular patterns (DAMPs) by necrotic cells leads to increased
cardiac inflammation that is mediated, at least in part, through Toll-like receptor 4 (TLR4) signaling pathways5;
second, a prior study in dysferlin null mice showed that there was less inflammation in mice that lacked MyD8811,
a canonical adaptor protein that interacts with TIR domain-containing proteins, and which mediates inflammatory signaling pathways through TLR signaling p
 athways12. The salient finding shown in Fig. 1B,C is that there
−/−
−/−
was less adverse LV remodeling in Dysf /Tirap mice at 2 or 4 weeks of age. Both LV EDV (p = 0.70 at 2 weeks,
p = 0.42 at 4 weeks) and ESV (p = 0.70 at 2 weeks, p = 0.78 at 4 weeks) were not significantly different than the
values observed in WT hearts. Moreover, LV EF (p = 0.069 at 2 weeks, p = 0.267 at 4 weeks) and LVM (p = 0.746
at 2 weeks, p = 0.678 at 4 weeks) were not significantly different in the Dysf−/−/Tirap−/− hearts when compared to
WT (Supplemental Figure S1). Both AAR and infarct size (Fig. 1A,D,E) were not significantly different in the
in Dysf−/−/Tirap−/− hearts when compared to WT (p > 0.999 and p = 0.724, respectively). Consistent with these
observations, the extent of EBD uptake was not significantly different (p > 0.999) in Dysf−/−/Tirap−/− and WT
hearts (Fig. 1F). Viewed together these findings show that the adverse LV remodeling observed in Dysf−/− mice is
TIRAP-dependent, which suggests that the adverse LV remodeling observed in the Dysf−/− mice was secondary
to collateral damage mediated by TIRAP-dependent myocardial inflammation.

I/R‑induced inflammation in dysferlin deficient mice is TIRAP dependent. Based on prior
studies demonstrating that increased membrane fragility in Dysf−/− mice leads to increased skeletal muscle
inflammation13 and demonstrating a role for TLR2 in I/R induced inflammation14, we hypothesized that membrane fragility contributed to the adverse LV remodeling in Dysf−/− hearts secondary to increased inflammation
that was mediated through TIRAP-dependent signaling pathways that were activated by the release of DAMPs
from damaged and/or dying cells. Figure 2A shows representative immunofluorescence staining of CD68+ cells
in Dysf−/− and WT hearts 2 weeks after closed-chest I/R injury; Fig. 2B summarizes the results of group data.
As shown, there was a significant (p = 0.002) increase in the number of CD68+ cells within the infarct zone of
the Dysf−/− hearts compared to WT hearts. We also observed a significant (p = 0.01) increase in Ly6G+ cells
(Fig. 2C,D) in the infarct zone of the Dysf−/− hearts when compared to WT hearts. Remarkably, there was no significant increase in CD68+ (p = 0.7) and Ly6G+ (p > 0.999) cells within the infarct zone of Dysf−/−/Tirap−/− hearts
when compared to WT hearts.
Bone marrow derived dysferlin deficient hematopoietic cells do not contribute to I/R‑induced
adverse LV remodeling in Dysf−/− mice. Given that dysferlin influences both the trafficking and func-

tion of immune cells15,16, we also performed experiments, wherein we reconstituted the bone marrow of Dysf−/−
mice with WT mice donor cells, as well as reciprocal experiments wherein we reconstituted the bone marrow
of WT mice with Dysf−/− donor cells, and then subjected these chimeric mice to I/R injury 8 weeks after they
were reconstituted. These studies showed that 2 weeks after I/R injury there was no difference in the AAR, LV
EDV, LV ESV, LV EF, nor LV mass in Dysf−/− → WT chimeric mice when compared to WT → WT chimeric mice
(see Supplemental Figure S2 for details). There was, however, a significant increase in LV EDV (p = 0.030) and
LV ESV (p = 0.041) in WT → Dysf−/− mice , suggesting that bone marrow derived dysferlin deficient cells do not
contribute to adverse LV remodeling after I/R injury in Dysf−/− mice.

Effect of Poloxamer 188 on I/R‑induced adverse LV remodeling in dysferlin deficient mice. The
findings that the increase in myocardial inflammation and adverse LV remodeling observed in Dysf−/− mouse
hearts was abrogated in Dysf−/−/Tirap−/− mouse hearts, but not in chimeric Tirap−/− → Dysf−/− mouse hearts suggested that the adverse phenotype in the Dysf−/− mouse hearts was cardiac autonomous. Noting that prior studies
demonstrated that dysferlin plays an important role in membrane sealing17,18, and that the membrane resealing
reagent Poloxamer 188 (P188) was cardioprotective in Dysf−/− mouse hearts subjected to I/R injury ex vivo2,10,
we sought to determine whether treatment with P188 would rescue the phenotype of the Dysf−/− mice subjected
to I/R injury in vivo. We first confirmed that in our hands P188 (10 µM) improved LV functional recovery
(p = 0.007) in Dysf−/− mouse hearts subjected to 30 min of no-flow ischemia, followed by 60 min of reperfusion
ex vivo (Supplemental Figure S3), as suggested by Martindale et al.10. Interestingly, recovery of LV function
following I/R injury ex vivo was not significantly different (p = 0.826) in WT hearts treated with P188 when
compared to diluent treated hearts. As we have reported p
 reviously8, there were small but statistically significant
differences in LV developed pressure between WT (Figure S3A) and Dysf−/− (Figure S3B) mouse hearts following
I/R injury (p = 0.035 by ANOVA).
After confirming that P188 was cardioprotective in Dysf−/− mice ex vivo, we treated WT and Dysf−/− mice
with P188 in vivo immediately after closed chest I/R injury. For these studies P188 (or diluent) was administered via the jugular vein immediately after reperfusion, followed by an i.p. injection of diluent or P188 6 h
later. Subsequently, the mice were given daily i.p injections of diluent or P188 up until the time of terminal
sacrifice at 14 days. Figure 3A shows that the AAR risk was not significantly different in the WT (p > 0.999)
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Figure 2.  Myocardial inflammation within the infarct zone of WT, Dysf−/−, Tirap−/− and Dysf−/−/Tirap−/− mouse
hearts following I/R injury. The extent of myocardial inflammation within the infarct zone was determined by
enumerating the number of CD68+ and Ly6G+ cells in the hearts of WT, Dysf−/−, Tirap−/− and Dysf−/−/Tirap−/−
mouse hearts 2 weeks after I/R injury. (A) Representative fluorescent images of CD68+ staining, (B) Group data
for the number of CD68+ cells (n = 4–6 myocardial sections/group), (C) Representative fluorescent images of
Ly6G+ staining, (D) Group data for the number of Ly6G + cells w (n = 4–6 myocardial sections/group). Scale
bars = 100 µm, Data are presented as mean ± SEM (*p < 0.05).

and Dysf−/− (p > 0.999) hearts treated with either diluent or P188. Consistent with our earlier studies (Fig. 1),
we observed a significant increase in LV remodeling in diluent treated Dysf−/− mice when compared to diluent
treated WT mice (LV EDV p = 0.0001; LV ESV p = 0.0003; Fig. 3). As shown in Fig. 3B,C, I/R-induced LV remodeling was not significantly different in the WT mice treated with P188 or diluent (LV EDV p > 0.999; LV ESV
p > 0.999). However, the salient finding shown by Fig. 3 and Supplemental Figure 4 is that treatment with P188
did not attenuate LV remodeling in the Dysf−/−mice, when compared to diluent treated Dysf−/− mice (LV EDV
p > 0.999; LV ESV p > 0.999). Infarct size was not significantly different in the P188 treated WT mice (p > 0.999)
or the P188 treated Dysf−/−mice (p > 0.999), relative to diluent treated WT and Dysf−/− mice.
To determine whether P188 had an effect on I/R-induced inflammation, we quantified the number of
CD68+ and Ly6G+ cells in diluent and P188 treated WT and Dysf−/− mouse hearts 2 weeks after I/R injury. Figure 4A shows representative immunofluorescence staining of CD68+ cells in diluent treated and P188 treated
Dysf−/− and WT hearts, whereas Fig. 4B summarizes the results of group data. As shown, there was a significant
increase in the number of CD68+ cells in the diluent (p = 0.012) and P188 (p = 0.020) treated Dysf−/− hearts when
compared to diluent and P188 treated WT mouse hearts. Figure 4C shows representative immunofluorescence
staining of Ly6G+ cells in diluent treated and P188 treated Dysf−/− and WT hearts 2 weeks after closed-chest
I/R injury, and Fig. 4D summarizes the results of group data. There was a significant increase (p = 0.003) in the
number of Ly6G+ cells in the diluent treated Dysf−/− hearts when compared to diluent treated WT mouse hearts.
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Figure 3.  Effect of Poloxamer 188 (P188) on LV remodeling and infarct size in WT and Dysf−/− mice following
I/R injury. WT and Dysf−/− mice, subjected to closed chest ischemia (60 min) or a sham procedure followed by
2 weeks of reperfusion, were treated with P188 or an equal volume of diluent immediately prior to reperfusion
and then daily for 14 days. Mice were imaged by 2-D echocardiography at baseline (pre-ischemia), during the
imposition of ischemia, and at 2 after reperfusion (n = 5–6/group). (A) Area-at-risk (AAR(SWMSI)), (B) Left
ventricular end-diastolic volume (EDV), (C) Left ventricular end-systolic volume (ESV) (D) Representative
images of trichrome staining of histological myocardial sections. 2 weeks after reperfusion, (E) Group data for
trichrome staining (expressed as a % of the LV myocardium) 2 weeks after reperfusion (n = 4–6 per group). Data
are presented as mean ± SEM (*p < 0.05 compared to WT).
There was also a significant increase (p = 0.022) in the number of Ly6G+ cells in the P188 treated Dysf−/− hearts
when compared to P188 treated WT mouse hearts. Although there was a numerical increase in the number of
CD68+ and Ly6G+ cells in the P188 treated WT hearts when compared to diluent treated hearts, these changes
were not statistically significant (p = 0.149 and 0.298, respectively). There was no significant difference in the
number of CD68+ (p = 0.365) and Ly6G+ (p > 0.999) cells in the diluent and P188 treated Dysf−/− hearts.
As a first step towards understanding why P188 was cytoprotective ex vivo, but had no effect in vivo, we
performed studies with P188 and cultured intraperitoneal macrophages (ipMACs). Based on a prior study
which showed that P188 activates immune c ells19, we asked whether P188 provoked increased IL-1β secretion
and increased phagocytosis in ipMACs. Figure 5A shows that stimulation with P188 did not increase (p > 0.999)
IL-1 β secretion when compared to diluent treated control ipMACs, whereas treatment with necrotic myocardial
cell extracts (NCEs) and LPS (positive control) provoked a significant (p = 0.006 and p = 0.0005 respectively)
increase in IL-1β secretion relative to diluent treated controls. Figure 5B, shows that relative to diluent treated
cells, treatment with P188 did not lead to increased phagocytic activity (p > 0.999), whereas stimulation with
necrotic myocardial extracts (NCEs) (p = 0.0002) and LPS (p = 0.0322) increased phagocytosis significantly. Lastly,
as shown in Fig. 5C, we observed that FITC- labeled P188 was internalized by ipMACs (18 h). Viewed together
these data suggest that although P188 is phagocytosed by macrophages, it has no intrinsic effect of macrophage
pro-inflammatory or phagocytic activities.

Discussion

The phospholipid bilayer sarcolemmal membrane that envelops cardiac myocytes presents the first line of defense
for preserving cell viability following myocardial injury. Here we show that dysferlin null mice, which lack an
effective membrane repair mechanism are more sensitive to I/R than WT mice, and undergo adverse LV remodeling secondary to sustained TIRAP-dependent inflammation within the infarct zone, resulting in increased
myocyte cell death and increased infarct size. The following lines of evidence support this statement. First, I/R
injury resulted in a significant increase in adverse cardiac remodeling in Dysf−/− mice, when compared to WT
controls (Fig. 1B). Although the area at risk was not significantly different in the WT and Dysf−/− mice (Fig. 1A),
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Figure 4.  Effect of Poloxamer 188 (P188) on myocardial inflammation within the infarct zone in WT
and Dysf−/− mice following I/R injury. The extent of myocardial inflammation within the infarct zone was
determined by enumerating the number of CD68+ and Ly6G+ cells in the hearts of diluent and P188 treated WT
and Dysf−/− mice 2 weeks following sham procedure or closed chest I/R injury. (A) Representative fluorescent
images of CD68+ staining within the infarct zone, (B) Group data for the number of CD68+ cells within the
infarct zone (n = 5–6 myocardial sections/group), (C) Representative fluorescent images of Ly6G+ staining
within the infarct zone, (D) Group data for the number of Ly6G+ cells within the infarct zone 2 weeks following
reperfusion (n = 5–6 myocardial sections/group). Scale bars = 100 µm. Data are presented as mean ± SEM
(*p < 0.05).
the infarct size at 2 weeks was significantly greater in the Dysf−/− mouse hearts (Fig. 1E). Consistent with the
increase in infarct size, we observed increased uptake of EBD in the Dysf−/− cardiac myocytes (Fig. 1F), suggesting that there was increased necrotic myocyte cell death in I/R injured Dysf−/− mouse hearts. Second, crossing
the Dysf−/− mice with Tirap−/− mice resulted in decreased EBD uptake (Fig. 1F), decreased inflammation in the
infarct zone (Fig. 2B,D), smaller infarct sizes (Fig. 1E), and less LV remodeling (Fig. 1B), when compared to
Dysf−/− mice. The adverse LV remodeling in the Dysf−/− mice was not affected by reconstituting the bone marrow
of the Dysf−/− mice with WT marrow (Supplemental Figure S2), demonstrating that the increased inflammation and adverse LV remodeling in Dysf–/– mice is mediated centrally and does not require Dysf–/- bone marrow
derived hematopoietic cells.
The observation that the increased inflammation within the infarct zone of Dysf−/− hearts was abrogated in
a TIRAP-deficient background (Fig. 2), suggests (but does not prove) that the inability to reseal membranes in
injured Dysf–/- mouse hearts results in the ongoing release of intracellular molecules (e.g. DAMPs) that engage
TLR2/TLR4 receptors on cardiac myocytes and resident immune cells within the infarct zone, leading to sustained inflammation. Similar findings have been observed in skeletal muscle of Dysf−/− mice13,20. Third, given that
increased membrane permeability has been proposed as one of the mechanisms for increased tissue injury and
inflammation in the Dysf−/− mice, we treated the Dysf−/− mice with P188, a non-ionic tri-block copolymer that
has been shown to seal membranes, at the time of reperfusion. As shown in Figs. 3 and 4, although treatment
with P188 prevented cardiac injury ex vivo, consistent with a prior r eport10, treatment with P188 did not decrease
myocardial inflammation, nor attenuate adverse cardiac remodeling following I/R injury in vivo.
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Figure 5.  Effect of Poloxamer 188 (P188) on isolated peritoneal macrophages (ipMACs). To determine
whether P188 had intrinsic effects on isolated peritoneal macrophages, we stimulated cultures of ipMACs for
24 h with diluent (control), necrotic myocardial cell extracts (NCEs) or LPS (positive controls), as well as P188.
(A) IL-1β levels in supernatants of ipMAC cultures (n = 4–6 samples/group), (B) Bead uptake by cultured
ipMACs (n = 4–10 samples per group), (C) Representative fluorescence images of FITC-labeled P188 uptake by
ipMACs following 18 h of incubation. DAPI staining (blue) was used to identify the nuclei of ipMACs. Scale bar
×20 = 100 µm. Scale bar ×40 = 50 µm. Data are presented as mean ± SEM (*p < 0.05 compared to control).

Membrane sealing and myocardial injury. Sarcolemmal integrity is preserved through several cardiac
myocyte cell autonomous mechanisms that either stabilize the membrane through phospholipid rearrangements
at the site of tissue injury, or directly promote membrane resealing. Thus far, studies have shown that a number
of different molecules play an integral role in maintaining membrane integrity including dysferlin, the dystrophin glycoprotein complex (DGC), Mitsugumin 53 (TRIM72), thrombospondin 4, synaptogamins, SNARE
proteins, the endosomal sorting complex required for transport and G
 RAF11,2,21–23. Dysferlin is a type II transmembrane protein belonging to the ferlin family of proteins which have been shown to play an important role
in membrane repair by facilitating Ca2+-mediated trafficking of vesicles to the site of membrane injury9,24. While
the absence of dysferlin is known to lead to skeletal muscle damage in limb girdle muscular dystrophy type 2B
and Miyoshi myopathy, the effects of dysferlin in the heart are less well known. Two prior studies have shown
that Dysf−/− mice have impaired ability to recover LV function following I/R injury ex vivo10,25. A prior in vivo
study by Han et al.17 demonstrated that infarct size and LV ejection fraction were not significantly different in
WT and Dysf−/− mice following acute coronary artery ligation. Our results significantly expand upon these acute
studies by demonstrating that the longer term sequelae of ischemic myocardial injury in Dysf−/− mice results in
significant infarct expansion secondary to TIRAP-dependent increased inflammation within the infarct zone.
Our findings in the heart are consistent with prior studies that showed that skeletal muscle performance was
improved in dysferlin-deficient mice when crossed with Myd88-deficient mice (TIRAP interacts directly with
MyD88)11,20. Uaesoontrachoon and colleagues hypothesized that breaches in the skeletal muscle membrane in
dysferlin-deficient mice resulted in the release of endogenous danger signals that bind to cognate TLR ligands on
muscle and immune cells, which in turn activate downstream processes that lead to the recruitment of inflammatory cells that worsen the initial damage caused by the dysferlin gene d
 efect11.
Several studies have used chemical-based membrane stabilizers, such as P188, to protect striated muscle
membranes2,10,26–28. P188 is composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene, and is currently approved by the Food and Drug Administration as an antiviscosity agent. The most well documented characteristic of P188 is its ability to repair damaged cell membranes
by mechanisms that are not entirely clear. It is believed that P188 inserts into areas of low membrane tension
(perhaps areas of membrane damage) due to its amphiphilic and hydrophobic properties29. P188 has been shown
to reduce infarct size following I/R injury in dogs and pigs when administered a cutely30–32. Moreover, a 30-min
intravenous infusion of high dose P188 (460 mg/kg) was shown to acutely (~ 40 h) improve LV ejection fraction
and decrease LV end-systolic volume when administered to rats 8 weeks after acute ligation of the left anterior
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descending artery27. Although we were able to confirm the findings of Martindale et al., which showed that
administration of P188 improved recovery of LV function in Dysf−/− subjected to I/R injury ex vivo (Supplemental
Figure S3)10, chronic treatment with P188 did not decrease infarct size, nor the extent of adverse LV remodeling
following I/R injury in the Dysf−/− mice. Although the reasons for the discrepancy between the present findings
and the prior short term studies are not known, one possibility is that the dose of P188 that we employed was
suboptimal for the experimental conditions studied herein. This statement notwithstanding, the dose and dosing
strategy used in the present study were based on recommendation by the manufacturer, prior in vivo studies with
P18827,31, as well as a pharmacokinetic study by the manufacturer that demonstrated the feasibility of the dose
that was chosen. A second interesting possibility suggested by our in vitro studies is that P188 was less bioavailable within the infarct zone because of phagocytic uptake by m
 acrophages33. While direct correlations between
relatively short-term experimental studies in mice and longer-term clinical studies in humans are not appropriate,
our data are consistent with the results of the CORE (Collaborative Organization for the RheothRx Evaluation)
phase II clinical trial, which did not show a benefit of P188 on the primary end point of mortality, reinfarction
or cardiogenic shock in patients with ST-segment myocardial infarction undergoing thrombolytic t herapy34.

Conclusions

This study reveals a previously unappreciated role for the importance of membrane sealing and the resolution of
inflammation following myocardial injury. The observation that inflammation was sustained within the infarct
zone of the hearts of Dysf−/− mice at a time when inflammation was completely resolved within the infarct zone
of WT mice suggests that the inability to reseal membranes in dysferlin-deficient injured cardiac myocytes results
in the sustained release of intracellular molecules (e.g. DAMPs) that engage TLR2/TLR4 receptors on cardiac
myocytes and immune cells within the infarct zone, leading to the activation of TIRAP-dependent signaling cascades that foster sustained recruitment of inflammatory cells to the infarct zone, resulting in increased cell death,
increased infarct size and adverse LV remodeling. While our studies focused on the role of TIRAP dependent
TLR2/4 mediated signaling, we cannot exclude an important role for endosomal TLRs or DNA-sensing receptor
cyclic GMP–AMP synthase (cGAS) and signaling effector stimulator of interferon genes (STING) in terms of
mediating sustained inflammation following I/R injury in Dysf−/− mouse hearts35. Given the increasing recognition that cytosolic proteins (e.g. troponin) are released from cardiac myocytes in non-ischemic settings36, the
results of the present studies also serve the heuristic purpose of focusing future studies on the role of membrane
integrity in the development of the chronic inflammation that occurs in the setting of hemodynamic pressure
and volume o
 verload37–39, as well as on the need to better understand the molecular pathways that regulate
membrane integrity in health and disease.

Methods

Study approval. All studies were performed with the approval of the Institutional Animal Care and Use
Committee at Washington University School of Medicine. These investigations conform to the Guide for the Care
and Use of Laboratory Animals, published by the National Institutes of Health.
Transgenic mouse lines. The dysferlin null mice (B6.129-Dysftm1Kcam/J[Dysf−/−], Jackson Labs) were main-

tained on a C57BL/6 background18. The Tirap−/− mice were a gift from Dr. Ruslan Medzhitov (Yale University,
New Haven, CT)40. Male Dysf−/− mice were crossed with Tirap−/− mice to generate Dysf−/−/Tirap−/− double knockout mice. The Dysf−/−/Tirap−/− mice were born with the expected Mendelian frequency and had normal life
spans. All mice were maintained in a pathogen‐free environment and were fed pellet food and water ad libitum.

Ischemia reperfusion (I/R) injury in vivo. WT, Dysf−/−, Tirap−/−, and Dysf−/−/Tirap−/− mice were subjected

to ischemia reperfusion (I/R) injury, using a closed-chest ischemia reperfusion model, as described41,42. We used
10–12 week old male mice, anesthetized with 1.5% isoflurane, that were subjected to 60 min of closed-chest
ischemia, followed by reperfusion for 2–4 weeks. Sham-operated animals underwent the identical procedure
with the exception that ischemia was not induced. For experiments using Poloxomer 188 (P188, MAST Therapeutics), mice were given 460 mg/kg P188 via jugular vein infusion immediately following reperfusion. Mice
were then given a bolus of 2,000 mg/kg P188 i.p. 6 h later. Daily i.p. injections of 460 mg/kg P188 were then given
for 14 days at which time echoes were performed and hearts were harvested for histology. The dose was determined based on the literature10,26, and the dosing strategy was based on prior studies by MAST Therapeutics.

Ischemia reperfusion (I/R) injury ex vivo.

Hearts from 10 to 12 week old male WT and Dysf−/− mice
were isolated and perfused at a constant pressure of 70 mmHg with modified Krebs–Henseleit buffer as described
previously8,43. After a 20-min stabilization period, hearts were subjected to no-flow ischemia (t = 0 min) for
30 min followed by reperfusion (t = 30 min) for up to 60 min (t = 90 min). For experiments with P188, Krebbs
Henseleit buffer was prepared with 10 µM P18810. KH buffer containing P188 was perfused during baseline and
during reperfusion. Functional data were recorded at 1 kHz on a data acquisition system (PowerLab; ADInstruments). LV developed pressure (LVDP) was calculated as the difference between peak systolic pressure and
LVEDP, and the resulting LV functional recovery data are expressed as the percentage of LVDP at baseline.

Echocardiographic studies. Image acquisition. Ultrasound examination of the cardiovascular system

was performed using a Vevo 2100 Ultrasound System (VisualSonics Inc, Toronto, Ontario, Canada) equipped
with a 30 MHz linear-array transducer, as previously described42.
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Imaging protocol. Mice were imaged by echocardiography at baseline and simultaneously during the imposition of closed-chest ischemia, and then at 2 weeks and 4 weeks after I/R injury to evaluate parameters of LV
remodeling as described43. Noninvasive evaluation of the AAR was performed by assessing the segmental wall
motion score index (SWMSI) at the time of reperfusion, as d
 escribed43. Isoflurane (1.5% inhaled via nose cone)
was used during ischemia and Avertin (0.005 ml/g) was used for sedation for imaging at 2 and 4 weeks based on
previously established methods for infarct quantitation in vivo42.

Evans Blue dye injection. 1% Evans Blue dye (Sigma, St. Louis, MO) in PBS was injected i.p. 18 h prior to

harvesting hearts. Hearts were harvested, perfused with 10 ml PBS followed by 10 ml Z-fix and allowed to sit in
Z-fix overnight before being transferred to 70% ethanol prior to paraffin e mbedding43.

Histologic analysis. Two weeks after I/R injury mice were euthanized and the hearts were removed and

processed, paraffin-embedded, and stained with hematoxylin/eosin and Masson’s trichrome44. To estimate the
volume fraction (%) of collagen, mid-papillary sections of Masson’s trichrome-stained sections were quantified
using color thresholding by ImageJ software (NIH, Bethesda, MD), and data were expressed as the average percentage of the left ventricle stained (n = 5–6 per group). To evaluate myocyte size, sections were deparaffinized,
rehydrated, and stained with fluorescent rhodamine-conjugated wheat germ agglutinin at 5ug/ml in 1% BSA, 1X
TBS (Vector Labs, Burlingame, CA). Fluorescence was visualized using a Zeiss confocal microscope, and digital
images were analyzed and measured with Zeiss Axiovision software45.
We enumerated the CD68+ and Ly6G+ cells in the heart via 10X tile scanning of the entire heart at the midpapillary level. Hearts were fixed in 4% PFA overnight and then transferred to 30% sucrose for 24 h prior to
embedding in OCT and flash freezing. Prior to immunostaining, frozen sections were washed briefly in PBS and
then blocked in 3% BSA/5% horse serum. Sections were then incubated with antibodies to CD68 (MCA1957,
Biorad) or Ly6G (551459, BD) followed by Alexa 555 conjugated secondary antibody incubation (A224134,
Fisher). Fluorescence was visualized using a Zeiss confocal microscope. Images (~ 70–130 per section) were
stitched together using the Axiovision software to form whole mid-papillary section images (Supplemental Figure S5) to visualize the infarct zone. CD68+ and Ly6G+ cells were then manually counted in each tile comprising
the infarct zone to quantitate.

Bone marrow transplantation. We established reciprocal Dysf−/− and WT chimeric mice after lethal irra-

diation and bone marrow reconstitution. Chimeric mice were generated as described46. Briefly, 4-week-old WT
and Dysf−/− mice were irradiated with 1,000 Rads and reconstituted via intravenous injection with congenic
5 × 106 bone marrow cells isolated from the tibias and femurs of 4 to 5-week-old WT mice to generate WT → WT
and Dysf−/− → WT chimeras. Mice were allowed 8 weeks to reconstitute the bone marrow before use for experiments.

Peritoneal macrophages. Intraperitoneal macrophages (ipMACs) were isolated as previously d escribed47.
Cultures of ipMACs were stimulated with diluent, P188 (1.5 mg/ml final concentration), necrotic myocardial
cell extracts (10 µg/ml; positive control)5, and lipopolysaccharide (100 ng/ml; positive control [Sigma, St. Louis,
MO]) for 24 h. IL-1β was measured in stimulated cell culture supernatants using an IL-1β ELISA kit (R&D kit
Cat. #MLB00C) according to the manufacturer’s instructions. The phagocytic capacity of stimulated cultures of
ipMACs was assessed by measuring phagocytosis of 0.5um Fluoresbrite yellow-green fluorescent polystyrene
microspheres (Polysciences Inc., Warrington, PA). For these experiments ipMACs were plated on coverslips and
incubated with microspheres for 2 h, at a ratio of 200 microspheres per cell, and then cultures were fixed with
4% paraformaldehyde. Cells were then incubated with anti CD68 antibody (#MCA1957, Biorad, Hercules, CA),
followed by incubation with goat anti-rat 594 secondary antibody (#A11007, Thermofisher, Waltham, MA) and
mounted with DAPI containing Vectashield mounting media (Vector Laboratories, Burlingame, CA). Fluorescence was imaged via confocal at 20× and quantitated. CD68 positive cells that had internalized more than 5
microspheres were considered positive for phagocytosis. In separate experiments, macrophages were incubated
with FITC-labeled P188 (1.5 mg/ml; prepared by the Center for Drug Discovery, Washington University and
Aris Pharma, Levittown, PA) for 18 h and the ipMACs imaged using fluoresence confocal microscopy.
Statistical analysis. Data are expressed as means ± SEM. One-way ANOVA with Bonferroni post-hoc

analysis (Graphpad Prism) was used to test for differences in EBD uptake, Trichrome staining, cell area, CD68
and Ly6G quantification. For repeated measures analysis, (2-D echocardiography and Langendorff perfusion
data), mixed models methodology or 2- way repeated measures ANOVA were used. For the mixed model, group,
time and the interaction between group and time were all entered into the model. Time was treated as a categorical variable. The interaction was evaluated to determine if the relationship between group and echo parameter
varied with respect to time. Based on the Akaike Information Criteria (AIC) and Shwarz Information Critieria (BIC), an unstructured variance–covariance matrix was used to model the repeated measurements. Group
means were based on model results and differences between groups were determined overall and within each
time point. All pair-wise comparisons were considered. Test results were adjusted based on Sidak’s method to
control the overall type I error rate. A value of p < 0.05 was considered statistically significant43.

Data availability

The authors agree to make all materials, data and associated protocols available to readers promptly without
undue qualifications in material transfer agreements.
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